Expression Profile of CYP1A1 and CYP1B1 Enzymes in Colon and Bladder Tumors

Background The cytochrome P450 CYP1A1 and CYP1B1 enzymes are involved in carcinogenesis via activation of pro-carcinogenic compounds to carcinogenic metabolites. CYP1A1 and CYP1B1 have shown elevated levels in human tumors as determined by qRT-PCR and immunohistochemical studies. However studies that have examined CYP1 expression by enzyme activity assays are limited. Results In the current study the expression of CYP1A1 and CYP1B1 was investigated in a panel of human tumors of bladder and colorectal origin by qRT-PCR and enzyme activity assays. The results demonstrated that 35% (7/20) of bladder tumors and 35% (7/20) of colon tumors overexpressed active CYP1 enzymes. CYP1B1 mRNA was overexpressed in 65% and 60% of bladder and colon tumors respectively, whereas CYP1A1 was overexpressed in 65% and 80% of bladder and colon tumors. Mean mRNA levels of CYP1B1 and CYP1A1 along with mean CYP1 activity were higher in bladder and colon tumors compared to normal tissues (p<0.05). Statistical analysis revealed CYP1 expression levels to be independent of TNM status. Moreover, incubation of tumor microsomal protein in 4 bladder and 3 colon samples with a CYP1B1 specific antibody revealed a large reduction (72.5 ± 5.5 % for bladder and 71.8 ± 7.2% for colon) in catalytic activity, indicating that the activity was mainly attributed to CYP1B1 expression. Conclusions The study reveals active CYP1 overexpression in human tumors and uncovers the potential use of CYP1 enzymes and mainly CYP1B1 as targets for cancer therapy.

[1]  G. Murray,et al.  Immunohistochemical Localization of Cytochrome P450 CYP1B1 in Breast Cancer with Monoclonal Antibodies Specific for CYP1B1 , 1999, Journal of Histochemistry and Cytochemistry.

[2]  H. McLeod,et al.  Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer , 2001, British Journal of Cancer.

[3]  Zhong Jiang,et al.  Overexpression of cytochrome P450 1A1 and its novel spliced variant in ovarian cancer cells: alternative subcellular enzyme compartmentation may contribute to carcinogenesis. , 2005, Cancer research.

[4]  S. Kasai,et al.  β-Catenin signaling induces CYP1A1 expression by disrupting adherens junctions in Caco-2 human colon carcinoma cells , 2013 .

[5]  J A McKay,et al.  Tumor-specific expression of cytochrome P450 CYP1B1. , 1997, Cancer research.

[6]  K. Gopinath,et al.  Expression Profiling of CYP1B1 in Oral Squamous Cell Carcinoma: Counterintuitive Downregulation in Tumors , 2011, PloS one.

[7]  Spencer S. Ericksen,et al.  Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid. , 2004, Biochemical pharmacology.

[8]  E. Sausville,et al.  DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. , 2005, Cancer research.

[9]  E. Gillam,et al.  Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[11]  R. Consolini,et al.  Antiproliferative effects of 5-fluorouracil and oxaliplatin in colon cancer cell lines: comparison of three different cytotoxicity assays. , 2013, Journal of Biological Regulators and Homeostatic Agents.

[12]  G. Murray,et al.  Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. , 1999, Cancer letters.

[13]  S. Curran,et al.  Cytochrome P450 Profile of Colorectal Cancer: Identification of Markers of Prognosis , 2005, Clinical Cancer Research.

[14]  T. Sutter,et al.  Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. , 1998, Carcinogenesis.

[15]  J. Liehr,et al.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  George D Wilson,et al.  Target validation of cytochrome P450 CYP1B1 in prostate carcinoma with protein expression in associated hyperplastic and premalignant tissue. , 2004, International journal of radiation oncology, biology, physics.

[17]  R. D. Bruno,et al.  Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. , 2007, Bioorganic & medicinal chemistry.

[18]  M. Bosenberg,et al.  Epigenetic silencing of novel tumor suppressors in malignant melanoma. , 2006, Cancer research.

[19]  M. Ingelman-Sundberg,et al.  Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity. , 2013, Journal of medicinal chemistry.

[20]  T. Shimada,et al.  Metabolic activation of polycyclic aromatic hydrocarbons to carcinogens by cytochromes P450 1A1 and1B1 , 2004, Cancer science.

[21]  G. Murray,et al.  Cytochrome P450 enzymes: novel options for cancer therapeutics. , 2004, Molecular cancer therapeutics.

[22]  S. Weidlich,et al.  Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 Expression , 2005, Molecular Pharmacology.

[23]  P. Cooper,et al.  Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder , 2012, Molecular Cancer Therapeutics.

[24]  Z. Dvořák,et al.  Xenobiotic-induced transcriptional regulation of xenobiotic metabolizing enzymes of the cytochrome P450 superfamily in human extrahepatic tissues. , 2008, Current drug metabolism.

[25]  V. Androutsopoulos,et al.  Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1-mediated metabolism , 2008, Breast Cancer Research.

[26]  K. Keyomarsi,et al.  Expression of cytochromes P450 in human breast tissue and tumors. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[27]  D. Spandidos,et al.  The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation. , 2013, The Journal of nutritional biochemistry.

[28]  M. Ingelman-Sundberg,et al.  Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. , 2002, Molecular pharmacology.

[29]  G. Perdew,et al.  12(R)-Hydroxy-5(Z),8(Z),10(E),14(Z)-eicosatetraenoic Acid [12(R)-HETE], an Arachidonic Acid Derivative, Is an Activator of the Aryl Hydrocarbon Receptor , 2008, Molecular Pharmacology.

[30]  A. Tsatsakis,et al.  Bioactivation of the citrus flavonoid nobiletin by CYP1 enzymes in MCF7 breast adenocarcinoma cells. , 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[31]  G. Murray,et al.  Cytochrome P450 CYP1B1 activity in renal cell carcinoma , 2004, British Journal of Cancer.

[32]  D. Scudiero,et al.  P450 enzyme expression patterns in the NCI human tumor cell line panel. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[33]  K. Matsuura,et al.  Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia , 2013, Molecular Cancer.

[34]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  J. Liehr,et al.  4-Hydroxylation of estrogens as marker of human mammary tumors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Potter,et al.  CYP1A1 Regulates Breast Cancer Proliferation and Survival , 2013, Molecular Cancer Research.

[37]  D. Nebert,et al.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.

[38]  G. Murray,et al.  Tumour cytochrome P450 and drug activation. , 2002, Current pharmaceutical design.

[39]  A. Sparreboom,et al.  Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention , 2006, Molecular Cancer Research.

[40]  A. Loaiza-Pérez,et al.  Aryl hydrocarbon receptor activation by aminoflavone: new molecular target for renal cancer treatment. , 2012, International journal of oncology.

[41]  T. Rižner,et al.  Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: Lower levels of CYP1B1 and increased expression of S-COMT , 2011, Molecular and Cellular Endocrinology.

[42]  P. Loadman,et al.  Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. , 2011, Chemical communications.

[43]  R. Millikan,et al.  Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. , 2007, Urology.

[44]  I. Roots,et al.  Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. , 2005, Cancer research.

[45]  A. Buchmann,et al.  Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the beta-catenin pathway. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[46]  J. Double,et al.  Cytochrome P450 1B1 (CYP1B1) is overexpressed in human colon adenocarcinomas relative to normal colon: implications for drug development. , 2003, Molecular cancer therapeutics.

[47]  M. Ingelman-Sundberg,et al.  Colon Cancer–Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins , 2013, Clinical Cancer Research.

[48]  G. Murray,et al.  Quantitative analysis of the Ah receptor/cytochrome P450 CYP1B1/CYP1A1 signalling pathway. , 2003, Biochemical pharmacology.